Shares of AnaptysBio (NASDAQ:ANAB) climbed ~12% in the premarket on Wednesday after the biotech said its lead asset, rosnilimab, reached the main goals in a mid-stage trial targeted at the autoimmune ...

Recognition of telehealth as an effective strategy for delivering treatment for substance use disorder (SUD) has raised hopes for improving access to this treatment in settings with limited ...

AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.

ANSWER: Both RA and MCTD are rheumatologic diseases that affect many systems of the body. MCTD is often considered an overlap ...

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

The positive trial results have not only demonstrated rosnilimab's potential in treating RA but have also validated AnaptysBio's scientific approach in targeting PD-1 co-inhibitory receptors on ...

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.

My husband, who is 71, has been having some short-term memory problems over the past two years. We recently saw his primary doctor, who asked him some questions ...

Intermittent fasting may benefit antioxidant and inflammatory markers in postmenopausal women with rheumatoid arthritis.

Women face a lot of health issues after menopause. Now in this article, we have mentioned whether early menopause increases ...

Lung ultrasound (LUS) may be an effective screening tool for interstitial lung disease in patients with asymptomatic rheumatoid arthritis.

Seropositive rheumatoid arthritis may be protective against the development of PAH, based on results of Mendelian randomization analyses.